个人简介：

Dr. Patrick Y. Lu Chairman of the Board, Executive Director, President & Chief Executive Officer Dr. Patrick Y. Lu founded and has led Sirnaomics from an early discovery startup to a siRNA therapeutics product company, with multiple programs currently at the clinical stage. Dr. Lu brings 25+ years of nucleic acid drug development experience at Novartis, Digene, and Intradigm, where he was a co-founder. He has helped Sirnaomics raising over $270 million and develop the novel siRNA therapeutic, STP705, for the treatment of cancer and fibrosis diseases.

公司简介：

Sirnaomics is the first to achieve positive Phase IIb clinical outcomes in oncology clinical-stage RNA therapeutics biopharmaceutical company with a strong presence in both Asia and the U.S. that is discovering and developing innovative drugs for indications with significant unmet medical needs and large market opportunities. We have built a professional international team for the discovery and development of RNAi therapeutics and mRNA vaccines and therapeutics, based on our proprietary drug delivery technology platforms.